Fact CheckerSign in

NCT01770418Active, not recruitingPhase 1/2

A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer

Source: ClinicalTrials.gov · Last updated 29 Sept 2026

Brief summary (registry, in English)

The purpose of this research study is to compare the effects (good and bad) on subjects and their cancer using standard chemotherapy in combination with hypofractionated proton radiation therapy. Hypofractionation is a technique that delivers higher daily doses of radiation over a shorter period of time.

Status (registry)
Active, not recruiting
Phase (registry)
Phase 1/2
Study type
Interventional
Enrollment
32 (actual)
First submitted
11 Jan 2013
Start date
1 Mar 2013
Primary completion date
31 Jan 2038
Lead sponsor
Proton Collaborative Group
Diseases
Lung cancer
NCT number
NCT01770418

What you commit to

  • Study type: Interventional · Phase 1/2
  • Participants enrolled: 32
  • From 1 Mar 2013 to the primary completion date, 31 Jan 2038
  • 6 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Prior radiotherapy to thoracic area.
  • Unintentional weight loss \>10% within 4 weeks prior to study registration.

Other

  • Evidence of distant metastasis (M1) involvement.
  • Pregnant and/or breast-feeding women, or patients (men and women) of child-producing potential not willing to use medically acceptable forms of contraception while on study treatment and for at least 12 months after study treatment. Pregnancy testing is not necessary for women who have had a hysterectomy or have not had a menstrual period for at least 24 consecutive months.

Who the study is looking for

  • Pathologically confirmed invasive non-small cell lung cancer within 12 weeks prior to study registration. OR Pathologically confirmed invasive non-small cell lung cancer within 6 months prior to study registration if the patient received induction chemotherapy.
  • AJCC (American Joint Committee on Cancer) 7th Ed. clinical stage II-III.
  • ECOG Performance status 0-1 within 8 weeks prior to study registration.
  • Patient must give study-specific informed consent on an IRB-approved consent prior to any research-related procedures or study treatment.
  • Patient must be at least 18 years old at the time of consent.
  • Patient must complete all required tests in section 4.
  • Lab results per the following within 4 weeks prior to study registration:
    • Absolute neutrophil count (ANC) \>1,800 cells/mm3.
    • Platelets \> = 100,000 cells/mm3.
    • Hemoglobin \> =10 g/dl. The use of transfusion or other intervention to achieve Hgb ≥10.0 g/dl is acceptable.
    • AST/SGOT and ALT/SGPT \< 2.5 x the institutional upper limit of normal (IULN).
  • Post exploratory thoracotomy must be done \> 3 weeks prior to study registration or patient did not have post exploratory thoracotomy.
  • PFT (pulmonary function test) with a FEV1 \> 0.75 liters/second within 16 weeks prior to study registration.
  • Patients must be evaluated by a thoracic surgeon, pulmonologist or medical oncologist and deemed medically or surgically unacceptable for resection.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (6)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Maryland Proton Treatment Center
Coordinator of this site? Confirm its status
BaltimoreUnited StatesUnknown status
Hampton University Proton Therapy Institute
Coordinator of this site? Confirm its status
HamptonUnited StatesUnknown status
University of Florida Proton Therapy Institute
Coordinator of this site? Confirm its status
JacksonvilleUnited StatesUnknown status
Oklahoma Proton Center
Coordinator of this site? Confirm its status
Oklahoma CityUnited StatesUnknown status
Princeton ProCure Management LLC
Coordinator of this site? Confirm its status
SomersetUnited StatesUnknown status
Northwestern Medicine Chicago Proton Center
Coordinator of this site? Confirm its status
WarrenvilleUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.